天竺综保区罕见病药品进口规模居全国首位

Core Insights - The Tianzhu Comprehensive Bonded Zone is establishing a rare disease drug guarantee pilot area by 2025, aiming to enhance open innovation and facilitate the import of rare disease medications, with a cumulative import value reaching 27.043 billion yuan, ranking first in the country [1] - Approximately 70% of rare diseases manifest in childhood, and the current domestic supply of rare disease drugs is limited, leading to significant challenges for patients due to lengthy and costly import processes [1][2] - The Tianzhu Comprehensive Bonded Zone is implementing measures such as pre-assessment, tracking review, and 24-hour customs clearance to streamline the import and distribution of rare disease medications, ensuring timely access for patients [1] Group 1 - The Tianzhu Comprehensive Bonded Zone aims to transition from "people waiting for drugs" to "drugs waiting for people" by improving the policy support system for rare disease treatments [2] - By 2025, the zone plans to establish a multi-tiered medication guarantee system, including the inclusion of 10 urgently needed rare disease drugs in the Beijing Universal Health Insurance overseas special drug list [2] - The construction of the rare disease drug guarantee pilot area is expected to attract over 30 domestic and international pharmaceutical companies, contributing to a medical trade scale of 100.093 billion yuan by 2025 [2]